Anemia of pregnancy in Liberia, West Africa: a therapeutic trial.

Research was conducted in Liberia, West Africa to ascertain which hematinics produce the best Hb response in women during the 3rd trimester of pregnancy. After obtaining background information, each of the 621 subjects was randomly assigned to one of four treatment groups. Group 1 was given 60 mg iron once daily, group 2 was given 60 mg iron 3 times daily, group 3 was given 60 mg iron 3 times daily plus a 5-mg folic acid tablet once daily, and group 4 was given the same treatment as group 3 but also a weekly antimalarial prophylactic. For comparison, 58 untreated women in their 3rd trimester were also studied. Before therapy the five groups were similar with respect to selected socioeconomic status, health, and dietary variables. Hb response to therapy was measured at 4-wk intervals from the 24th wk of gestation until term. The Hb rises in all four treatment groups were significantly (p less than 0.001) higher than the base-line values at 4, 8, and 12 wk after the interventions. The percentage of anemic women was reduced from 78 to 45% over the 12 wk of supplementation. Hb rises in groups 3 and 4 were not significantly different from those in groups receiving iron alone. It is concluded that iron deficiency is the main cause of anemia in this population.